Cell therapy for Parkinson-type multiple system atrophy
Part of Brain & nervous system clinical trials.
This study tests whether injecting special dopamine-producing brain cells can help slow or improve symptoms in people with multiple system atrophy, a rare movement disorder similar to Parkinson's disease. The trial combines cell transplantation with brain imaging to measure safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 30–75 years old
- Diagnosed with Parkinson-type multiple system atrophy within the last 5 years
- Able to undergo brain surgery and general anesthesia
- No dementia, schizophrenia, severe depression, or severe anxiety
- No serious infections (hepatitis, HIV) or active cancer history
- Willing to use contraception if of childbearing age; no pregnancy or recent vaccines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a patient's own stem cells can help slow or improve symptoms of multiple system atrophy (MSA), a rare brain disorder. It may be an option for adults aged 35 to 65 with either the parkinsonian or cerebellar type of MSA.
This study tests a new injection called NouvNeu001 for people with Multiple System Atrophy (MSA). The goal is to see if it can help control symptoms that standard treatments aren't managing well.
This trial tests whether a medication called butylphthalide can help slow or improve symptoms of multiple system atrophy (MSA), a rare neurological condition that affects movement, balance, and automatic body functions. The study will measure how well the drug works and how safe it is for patients.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This trial tests a new cell treatment for Parkinson's disease. It involves injecting special cells into the brain to see if they can safely replace damaged cells and improve symptoms. It might help people who have had Parkinson's for several years and still respond well to medication.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
Hear when a new the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.